FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Wim van der Vijgh

Research Profile

Chemicals & Drugs

Living Beings

Procedures

High Pressure Liquid Chromatography

Concepts & Ideas

Disorders

Co-author Network

Publications

TOP 3
H Jacobs; Ger H Koek; M Moalin; R Peters; J Tack; Wim J F van der Vijgh; Aalt Bast; Guido R M M Haenen
Differences in pharmacological activities of the antioxidant flavonoid monoHER in humans and mice are caused by variations in its metabolic profile.
Hilde Jacobs; Mohamed Moalin; Wim J F van der Vijgh; Marike W van Gisbergen; Aalt Bast; Guido R M M Haenen
An essential difference in the reactivity of the glutathione adducts of the structurally closely related flavonoids monoHER and quercetin.
Hilde Jacobs; Ron Peters; Gertjan J M den Hartog; Wim J F van der Vijgh; Aalt Bast; Guido R M M Haenen
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Wim van der Vijgh (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: H Jacobs; Ger H Koek; M Moalin; R Peters; J Tack; Wim J F van der Vijgh; Aalt Bast; Guido R M M Haenen
Differences in pharmacological activities of the antioxidant flavonoid monoHER in humans and mice are caused by variations in its metabolic profile.
Clinical pharmacology and therapeutics 2011;90(6):852-9.
2011: Hilde Jacobs; Mohamed Moalin; Wim J F van der Vijgh; Marike W van Gisbergen; Aalt Bast; Guido R M M Haenen
An essential difference in the reactivity of the glutathione adducts of the structurally closely related flavonoids monoHER and quercetin.
Free radical biology & medicine 2011;51(11):2118-23.
2011: Hilde Jacobs; Ron Peters; Gertjan J M den Hartog; Wim J F van der Vijgh; Aalt Bast; Guido R M M Haenen
Identification of the metabolites of the antioxidant flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside in mice.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):750-6.
2010: Hilde Jacobs; Mohamed Moalin; Aalt Bast; Wim J F van der Vijgh; Guido R M M Haenen
An essential difference between the flavonoids monoHER and quercetin in their interplay with the endogenous antioxidant network.
PloS one 2010;5(11):e13880.
2009: Hilde Jacobs; Wim J F van der Vijgh; Ger H Koek; Guy J J Draaisma; Mohamed Moalin; Gino P F van Strijdonck; Aalt Bast; Guido R M M Haenen
Characterization of the glutathione conjugate of the semisynthetic flavonoid monoHER.
Free radical biology & medicine 2009;46(12):1567-73.
2007: Anna M E Bruynzeel; Hans W M Niessen; Jean G F Bronzwaer; Jacobus J M van Der Hoeven; Johannes Berkhof; Aalt Bast; Wim J F van der Vijgh; Cees J van Groeningen
The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study.
British journal of cancer 2007;97(8):1084-9.
2007: Helena Kaiserová; Tomás Simůnek; Wim J F van der Vijgh; Aalt Bast; Eva Kvasnicková
Flavonoids as protectors against doxorubicin cardiotoxicity: role of iron chelation, antioxidant activity and inhibition of carbonyl reductase.
Biochimica et biophysica acta 2007;1772(9):1065-74.
2007: Anna M E Bruynzeel; Suzanne Vormer-Bonne; Aalt Bast; Hans W M Niessen; Wim J F van der Vijgh
Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice.
Cancer chemotherapy and pharmacology 2007;60(4):509-14.
2007: Anna M E Bruynzeel; Mohamed A I Abou El Hassan; Casper G Schalkwijk; Johannes Berkhof; Aalt Bast; Hans W M Niessen; Wim J F van der Vijgh
Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice.
British journal of cancer 2007;96(6):937-43.
2007: Anna M E Bruynzeel; Mohamed A I Abou El Hassan; Emine Torun; Aalt Bast; Wim J F van der Vijgh; Frank A E Kruyt
Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells.
British journal of cancer 2007;96(3):450-6.
2007: Aalt Bast; Guido R M M Haenen; Anna M E Bruynzeel; Wim J F van der Vijgh
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Cardiovascular toxicology 2007;7(2):154-9.
2007: Bashir M Rezk; Wim J F van der Vijgh; Aalt Bast; Guido R M M Haenen
Alpha-tocopheryl phosphate is a novel apoptotic agent.
Frontiers in bioscience : a journal and virtual library 2007;12():2013-9.
2007: Aalt Bast; Helena Kaiserová; Gertjan J M den Hartog; Guido R M M Haenen; Wim J F van der Vijgh
Protectors against doxorubicin-induced cardiotoxicity: flavonoids.
Cell biology and toxicology 2007;23(1):39-47.
2006: Anna M E Bruynzeel; Paula P N Mul; Johannes Berkhof; Aalt Bast; Hans W M Niessen; Wim J F van der Vijgh
The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice.
Cancer chemotherapy and pharmacology 2006;58(5):699-702.
2006: Judith R Kroep; Egbert F Smit; Giuseppe Giaccone; Kasper van der Born; Jos H Beijnen; Cees J van Groeningen; Wim J F van der Vijgh; Pieter E Postmus; HERBERT PINEDO; Godefridus J Peters
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2006;58(4):509-16.
2006: Anja M Willems; Anna M E Bruynzeel; Marc A Kedde; Cees J van Groeningen; Aalt Bast; Wim J F van der Vijgh
A phase I study of monohydroxyethylrutoside in healthy volunteers.
Cancer chemotherapy and pharmacology 2006;57(5):678-84.
2006: Godefridus J Peters; Catharina J A Van Moorsel; Bianca Lakerveld; Kees Smid; Paul Noordhuis; Elizabeth C Comijn; Dennis Weaver; James Willey; Daphne Voorn; Wim J F van der Vijgh; HERBERT PINEDO
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
International journal of oncology 2006;28(1):237-44.
2005: Epie Boven; Marjan J Westerman; Cees J van Groeningen; Miranda Verschraagen; Rita Ruijter; I Zegers; Wim J F van der Vijgh; Giuseppe Giaccone
Phase I and pharmacokinetic study of the novel chemoprotector BNP7787 in combination with cisplatin and attempt to eliminate the hydration schedule.
British journal of cancer 2005;92(9):1636-43.
2004: Lucia De Franceschi; Franco Turrini; Marek Honczarenko; Kodjo Ayi; Alicia Rivera; Mark D Fleming; Terry Law; Franca Mannu; Frans A Kuypers; Aalt Bast; Wim J F van der Vijgh; Carlo Brugnara
In vivo reduction of erythrocyte oxidant stress in a murine model of beta-thalassemia.
Haematologica 2004;89(11):1287-98.
2004: Miranda Verschraagen; Epie Boven; Emine Torun; FREDERICK HAUSHEER; Aalt Bast; Wim J F van der Vijgh
Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Biochemical pharmacology 2004;68(3):493-502.
2004: Bashir M Rezk; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
The extraordinary antioxidant activity of vitamin E phosphate.
Biochimica et biophysica acta 2004;1683(1-3):16-21.
2004: Giuseppe Giaccone; J L González-Larriba; A T van Oosterom; R Alfonso; Egbert F Smit; M Martens; Godefridus J Peters; Wim J F van der Vijgh; R Smith; Steven D Averbuch; Abderrahim Fandi
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(5):831-8.
2004: Miranda Verschraagen; Epie Boven; Emine Torun; C A M Erkelens; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
British journal of cancer 2004;90(8):1654-9.
2004: Bashir M Rezk; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
Lipoic acid protects efficiently only against a specific form of peroxynitrite-induced damage.
The Journal of biological chemistry 2004;279(11):9693-7.
2004: Gertjan J M den Hartog; Guido R M M Haenen; Epie Boven; Wim J F van der Vijgh; Aalt Bast
Lecithinized copper,zinc-superoxide dismutase as a protector against doxorubicin-induced cardiotoxicity in mice.
Toxicology and applied pharmacology 2004;194(2):180-8.
2003: Bashir M Rezk; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore.
FEBS letters 2003;555(3):601-5.
2003: Mohamed A I Abou El Hassan; M J W E Rabelink; Wim J F van der Vijgh; Aalt Bast; Rob Hoeben
A comparative study between catalase gene therapy and the cardioprotector monohydroxyethylrutoside (MonoHER) in protecting against doxorubicin-induced cardiotoxicity in vitro.
British journal of cancer 2003;89(11):2140-6.
2003: Mohamed A I Abou El Hassan; Marc A Kedde; Ursula T H Zwiers; E Tourn; Guido R M M Haenen; Aalt Bast; Wim J F van der Vijgh
Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice.
Cancer chemotherapy and pharmacology 2003;52(5):371-6.
2003: Miranda Verschraagen; Epie Boven; Rita Ruijter; Kasper van der Born; Johannes Berkhof; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Clinical pharmacology and therapeutics 2003;74(2):157-69.
2003: Mohamed A I Abou El Hassan; Hendrik Verheul; Anita S Jorna; Casper G Schalkwijk; J van Bezu; Wim J F van der Vijgh; Aalt Bast
The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.
British journal of cancer 2003;89(2):357-62.
2003: Miranda Verschraagen; Epie Boven; Ivon Zegers; FREDERICK HAUSHEER; Wim J F van der Vijgh
Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Cancer chemotherapy and pharmacology 2003;51(6):525-9.
2003: Miranda Verschraagen; Marc A Kedde; FREDERICK HAUSHEER; Wim J F van der Vijgh
The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Cancer chemotherapy and pharmacology 2003;51(6):499-504.
2003: Miranda Verschraagen; T H Ursula Zwiers; Emine Torun; Martin G Donker; Nico J Reinhoud; Wim J F van der Vijgh
Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Journal of pharmaceutical sciences 2003;92(5):1040-50.
2003: Mohamed A I Abou El Hassan; Marc A Kedde; Ursula T H Zwiers; Aalt Bast; Wim J F van der Vijgh
The cardioprotector monoHER does not interfere with the pharmacokinetics or the metabolism of the cardiotoxic agent doxorubicin in mice.
Cancer chemotherapy and pharmacology 2003;51(4):306-10.
2003: Mohamed A I Abou El Hassan; M Heijn; M J W E Rabelink; Wim J F van der Vijgh; Aalt Bast; Rob Hoeben
The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells.
Cancer gene therapy 2003;10(4):270-7.
2003: Gertjan J M den Hartog; Agnes W Boots; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
Lack of inhibition of endothelial nitric oxide synthase in the isolated rat aorta by doxorubicin.
Toxicology in vitro : an international journal published in association with BIBRA 2003;17(2):165-7.
2003: Gertjan J M den Hartog; Guido R M M Haenen; Erik Vegt; Wim J F van der Vijgh; Aalt Bast
Superoxide dismutase: the balance between prevention and induction of oxidative damage.
Chemico-biological interactions 2003;145(1):33-9.
2003: Miranda Verschraagen; Marjolein Bosma; T H Ursula Zwiers; Emine Torun; Wim J F van der Vijgh
Quantification of mesna and total mesna in kidney tissue by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;783(1):33-42.
2002: Bashir M Rezk; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids.
Biochemical and biophysical research communications 2002;295(1):9-13.
2002: Gertjan J M den Hartog; Erik Vegt; Wim J F van der Vijgh; Guido R M M Haenen; Aalt Bast
Hypochlorous acid is a potent inhibitor of acetylcholinesterase.
Toxicology and applied pharmacology 2002;181(3):228-32.
2002: Miranda Verschraagen; Kasper van der Born; T H Ursula Zwiers; Wim J F van der Vijgh
Simultaneous determination of intact cisplatin and its metabolite monohydrated cisplatin in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;772(2):273-81.
2002: Epie Boven; Miranda Verschraagen; Theresia M Hulscher; C A M Erkelens; FREDERICK HAUSHEER; HERBERT PINEDO; Wim J F van der Vijgh
BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
European journal of cancer (Oxford, England : 1990) 2002;38(8):1148-56.
2002: Bart C Kuenen; Lee Rosen; Egbert F Smit; Mandy R N Parson; Marcel Levi; Rita Ruijter; Holger Huisman; Marc A Kedde; Paul Noordhuis; Wim J F van der Vijgh; Godefridus J Peters; Gillian F Cropp; Paul Scigalla; Klaas Hoekman; HERBERT PINEDO; Giuseppe Giaccone
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1657-67.
2002: Gertjan J M den Hartog; Guido R M M Haenen; Erik Vegt; Wim J F van der Vijgh; Aalt Bast
Efficacy of HOCl scavenging by sulfur-containing compounds: antioxidant activity of glutathione disulfide?
Biological chemistry 2002;383(3-4):709-13.
2002: J M G H van Riel; Cees J van Groeningen; Marc A Kedde; Helen Gall; Johanna M A Leisink; Gabriella Gruia; HERBERT PINEDO; Wim J F van der Vijgh; Giuseppe Giaccone
Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(2):405-12.
2001: FA van Acker; Janneke W Hulshof; Guido R M M Haenen; Wiro M P B Menge; Wim J F van der Vijgh; Aalt Bast
New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity.
Free radical biology & medicine 2001;31(1):31-7.
2001: Mohamed A I Abou El Hassan; Marc A Kedde; Aalt Bast; Wim J F van der Vijgh
Determination of monohydroxyethylrutoside in heart tissue by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(1):191-6.
2001: FA van Acker; Epie Boven; Klaas Kramer; Guido R M M Haenen; Aalt Bast; Wim J F van der Vijgh
Frederine, a new and promising protector against doxorubicin-induced cardiotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1378-84.
2001: Miranda Verschraagen; T H Ursula Zwiers; P E de Koning; J Welink; Wim J F van der Vijgh
Quantification of BNP7787 (dimesna) and its metabolite mesna in human plasma and urine by high-performance liquid chromatography with electrochemical detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;753(2):293-302.
2001: M A El Hassan; Marc A Kedde; Aalt Bast; Wim J F van der Vijgh
High-performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside in plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;752(1):115-21.
2001: C G Heijnen; Guido R M M Haenen; FA van Acker; Wim J F van der Vijgh; Aalt Bast
Flavonoids as peroxynitrite scavengers: the role of the hydroxyl groups.
Toxicology in vitro : an international journal published in association with BIBRA 2001;15(1):3-6.
2000: Mohamed A I Abou El Hassan; D J Touw; Abraham Wilhelm; Aalt Bast; Wim J F van der Vijgh
Stability of monoHER in an aqueous formulation for i.v. administration.
International journal of pharmaceutics 2000;211(1-2):51-6.
2000: Catharina J A Van Moorsel; HERBERT PINEDO; Kees Smid; Elizabeth M Comijn; Daphne Voorn; Gijsbert Veerman; B Lakerveld; Wim J F van der Vijgh; Giuseppe Giaccone; Pieter E Postmus; Godefridus J Peters
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
European journal of cancer (Oxford, England : 1990) 2000;36(18):2420-9.
2000: FA van Acker; Saskia van Acker; Guido R M M Haenen; Aalt Bast; Wim J F van der Vijgh
In vitro screening of antitumour agents for cardiotoxicity by means of isolated mouse left atria.
Anticancer research 2000;20(6B):4483-7.
2000: M Dijkgraaf-Ten Bolscher; Simone J M Neele; Rob Barto; Wim J F van der Vijgh; JAN COEN NETELENBOS
Effect of estrogen on intestinal strontium absorption in postmenopausal women.
Maturitas 2000;36(3):195-201.
2000: FA van Acker; J A Hageman; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast; Wiro M P B Menge
Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity.
Journal of medicinal chemistry 2000;43(20):3752-60.
2000: FA van Acker; O Schouten; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
Flavonoids can replace alpha-tocopherol as an antioxidant.
FEBS letters 2000;473(2):145-8.
2000: M Dijkgraaf-Ten Bolscher; Rob Barto; Daphne Voorn; D Compas; JAN COEN NETELENBOS; Wim J F van der Vijgh
Influence of ovariectomy on extracellular fluid volume in rats: assessment of extracellular fluid volume by means of bromide.
The Journal of laboratory and clinical medicine 2000;135(4):303-8.
2000: Cees J van Groeningen; Wim J F van der Vijgh; J J Baars; H Stieltjes; K Huibregtse; HERBERT PINEDO
Altered pharmacokinetics and metabolism of CPT-11 in liver dysfunction: a need for guidelines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1342-6.
2000: FA van Acker; Saskia van Acker; Klaas Kramer; Guido R M M Haenen; Aalt Bast; Wim J F van der Vijgh
7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(4):1337-41.
2000: M Dijkgraaf-Ten Bolscher; JAN COEN NETELENBOS; Rob Barto; Wim J F van der Vijgh
Strontium as a marker for intestinal calcium absorption: the stimulatory effect of calcitriol.
Clinical chemistry 2000;46(2):248-51.
1999: J Welink; Epie Boven; Jan B Vermorken; Helen Gall; Wim J F van der Vijgh
Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2349-58.
1999: M ten Bolscher; JAN COEN NETELENBOS; Rob Barto; L M Van Buuren; Wim J F van der Vijgh
Estrogen regulation of intestinal calcium absorption in the intact and ovariectomized adult rat.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(7):1197-202.
1999: Catharina J A Van Moorsel; HERBERT PINEDO; Gijsbert Veerman; André Bergman; CM Kuiper; Jan B Vermorken; Wim J F van der Vijgh; Godefridus J Peters
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
British journal of cancer 1999;80(7):981-90.
1999: HG Goovaerts; Th J C Faes; Gerdien W de Valk-de Roo; M ten Bolscher; J C Netelenbosch; Wim J F van der Vijgh; Rob M Heethaar
Estimation of extracellular volume by a two-frequency measurement.
Annals of the New York Academy of Sciences 1999;873():99-104.
1999: Catharina J A Van Moorsel; Judith R Kroep; HERBERT PINEDO; Gijsbert Veerman; Daphne Voorn; Pieter E Postmus; Jan B Vermorken; Cees J van Groeningen; Wim J F van der Vijgh; Godefridus J Peters
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(4):441-8.
1999: M ten Bolscher; Gerdien W de Valk-de Roo; Rob Barto; Wim J F van der Vijgh; JAN COEN NETELENBOS
Oestrogen has no short-term effect on intestinal strontium absorption in healthy postmenopausal women.
Clinical endocrinology 1999;50(3):387-92.
1999: Klaas Hoekman; Wim J F van der Vijgh; J B Vermorken
Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.
Drugs 1999;57(2):133-55.
1999: MJ Welters; AM Fichtinger-Schepman; RA Baan; AJ Jacobs-Bergmans; A Kegel; Wim J F van der Vijgh; Boudewijn J M Braakhuis
Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo.
British journal of cancer 1999;79(1):82-8.
1999: MJ Welters; Boudewijn J M Braakhuis; AJ Jacobs-Bergmans; A Kegel; RA Baan; Wim J F van der Vijgh; AM Fichtinger-Schepman
The potential of plantinum-DNA adduct determination in ex vivo treated tumor fragments for the prediction of sensitivity to cisplatin chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(1):97-103.
1998: HG Goovaerts; Th J C Faes; Gerdien W de Valk-de Roo; M ten Bolscher; J C Netelenbosch; Wim J F van der Vijgh; Rob M Heethaar
Extra-cellular volume estimation by electrical impedance--phase measurement or curve fitting: a comparative study.
Physiological measurement 1998;19(4):517-26.
1998: Saskia van Acker; G P van Balen; D J van den Berg; Aalt Bast; Wim J F van der Vijgh
Influence of iron chelation on the antioxidant activity of flavonoids.
Biochemical pharmacology 1998;56(8):935-43.
1998: J van Ark-Otte; Marc A Kedde; Wim J F van der Vijgh; AM Dingemans; WJ Jansen; HERBERT PINEDO; Epie Boven; Giuseppe Giaccone
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
British journal of cancer 1998;77(12):2171-6.
1998: AE Korst; Epie Boven; ML van der Sterre; AM Fichtinger-Schepman; Wim J F van der Vijgh
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
European journal of cancer (Oxford, England : 1990) 1998;34(3):412-6.
1998: AE Korst; ML van der Sterre; Helen Gall; AM Fichtinger-Schepman; Jan B Vermorken; Wim J F van der Vijgh
Influence of amifostine on the pharmacokinetics of cisplatin in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):331-6.
1997: Giuseppe Giaccone; SC Linn; J Welink; G Catimel; H Stieltjes; Wim J F van der Vijgh; CM Eeltink; Jan B Vermorken; HERBERT PINEDO
A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2005-15.
1997: Saskia van Acker; Epie Boven; K Kuiper; D J van den Berg; JA Grimbergen; Klaas Kramer; Aalt Bast; Wim J F van der Vijgh
Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(10):1747-54.
1997: Aafke H Honkoop; ELSKEN VAN DER WALL; Nicole Feller; Gerrit J Schuurhuis; Wim J F van der Vijgh; Epie Boven; Cees J van Groeningen; Giuseppe Giaccone; Klaas Hoekman; Jan B Vermorken; John Wagstaff; HERBERT PINEDO
Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):957-62.
1997: MJ Welters; M Maliepaard; AJ Jacobs-Bergmans; RA Baan; J H Schellens; J Ma; Wim J F van der Vijgh; Boudewijn J M Braakhuis; AM Fichtinger-Schepman
Improved 32P-postlabelling assay for the quantification of the major platinum-DNA adducts.
Carcinogenesis 1997;18(9):1767-74.
1997: AE Korst; CM Eeltink; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of amifostine and its metabolites in patients.
European journal of cancer (Oxford, England : 1990) 1997;33(9):1425-9.
1997: AE Korst; Jan B Vermorken; Wim J F van der Vijgh
High-performance liquid chromatographic assay using electrochemical detection for the combined measurement of amifostine, WR 1065 and the disulfides in plasma.
Journal of chromatography. B, Biomedical sciences and applications 1997;693(1):167-74.
1997: MJ Welters; AM Fichtinger-Schepman; RA Baan; Mario A J A Hermsen; Wim J F van der Vijgh; Jacqueline Cloos; Boudewijn J M Braakhuis
Relationship between the parameters cellular differentiation, doubling time and platinum accumulation and cisplatin sensitivity in a panel of head and neck cancer cell lines.
International journal of cancer. Journal international du cancer 1997;71(3):410-5.
1997: AE Korst; ML van der Sterre; CM Eeltink; AM Fichtinger-Schepman; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(5):697-703.
1997: A J Sips; Rob Barto; JAN COEN NETELENBOS; Wim J F van der Vijgh
Preclinical screening of the applicability of strontium as a marker for intestinal calcium absorption.
The American journal of physiology 1997;272(3 Pt 1):E422-8.
1997: AE Korst; Epie Boven; ML van der Sterre; AM Fichtinger-Schepman; Wim J F van der Vijgh
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
British journal of cancer 1997;75(10):1439-46.
1996: Saskia van Acker; Marcel J de Groot; D J van den Berg; M N Tromp; G Donné-Op den Kelder; Wim J F van der Vijgh; Aalt Bast
A quantum chemical explanation of the antioxidant activity of flavonoids.
Chemical research in toxicology 1996;9(8):1305-12.
1996: Epie Boven; J de Jong; CM Kuiper; A Bast; Wim J F van der Vijgh
Relationship between the tumour tissue pharmacokinetics and the antiproliferative effects of anthracyclines and their metabolites.
European journal of cancer (Oxford, England : 1990) 1996;32A(8):1382-7.
1996: A J Sips; Wim J F van der Vijgh; Rob Barto; JAN COEN NETELENBOS
Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.
British journal of clinical pharmacology 1996;41(6):543-9.
1996: J Welink; B Pechstein; Wim J F van der Vijgh
Determination of the two diastereoisomers of lobaplatin (D-19466) in plasma ultrafiltrate of cancer patients with a normal or an impaired kidney or liver function by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical applications 1996;675(1):107-11.
1996: AE Korst; Helen Gall; Jan B Vermorken; Wim J F van der Vijgh
Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient.
Cancer chemotherapy and pharmacology 1996;39(1-2):162-6.
1996: Wim J F van der Vijgh; AE Korst
Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 4():S26-30.
1996: Saskia van Acker; D J van den Berg; M N Tromp; D H Griffioen; W P van Bennekom; Wim J F van der Vijgh; Aalt Bast
Structural aspects of antioxidant activity of flavonoids.
Free radical biology & medicine 1996;20(3):331-42.
1996: Saskia van Acker; Klaas Kramer; Emile E Voest; J A Grimbergen; J Zhang; Wim J F van der Vijgh; Aalt Bast
Doxorubicin-induced cardiotoxicity monitored by ECG in freely moving mice. A new model to test potential protectors.
Cancer chemotherapy and pharmacology 1996;38(1):95-101.
1995: Klaas Kramer; Saskia van Acker; J A Grimbergen; D J van den Berg; Wim J F van der Vijgh; Aalt Bast
Effect of dimethyl sulfoxide (DMSO) on the electrocardiogram (ECG) in freely moving male Balb/c mice.
General pharmacology 1995;26(6):1403-7.
1995: A J Sips; Wim J F van der Vijgh; Rob Barto; JAN COEN NETELENBOS
Intestinal strontium absorption: from bioavailability to validation of a simple test representative for intestinal calcium absorption.
Clinical chemistry 1995;41(10):1446-50.
1995: Saskia van Acker; M N Tromp; Guido R M M Haenen; Wim J F van der Vijgh; Aalt Bast
Flavonoids as scavengers of nitric oxide radical.
Biochemical and biophysical research communications 1995;214(3):755-9.
1995: M E Ooms; Paul Lips; J C Roos; Wim J F van der Vijgh; Corry Popp-Snijders; P D Bezemer; L M Bouter
Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1995;10(8):1177-84.
1995: Rob Barto; A J Sips; Wim J F van der Vijgh; JAN COEN NETELENBOS
Sensitive method for analysis of strontium in human and animal plasma by graphite furnace atomic absorption spectrophotometry.
Clinical chemistry 1995;41(8 Pt 1):1159-63.
1995: Saskia van Acker; Klaas Kramer; J A Grimbergen; D J van den Berg; Wim J F van der Vijgh; Aalt Bast
Monohydroxyethylrutoside as protector against chronic doxorubicin-induced cardiotoxicity.
British journal of pharmacology 1995;115(7):1260-4.
1995: A J Sips; JAN COEN NETELENBOS; Rob Barto; Wim J F van der Vijgh
Measurement of intestinal calcium absorption by using stable strontium.
Clinical science (London, England : 1979) 1995;89(1):107.
1995: M E Ooms; J C Roos; P D Bezemer; Wim J F van der Vijgh; L M Bouter; Paul Lips
Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial.
The Journal of clinical endocrinology and metabolism 1995;80(4):1052-8.
1995: Godefridus J Peters; Wim J F van der Vijgh
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (WR-2721): preclinical aspects.
European journal of cancer (Oxford, England : 1990) 1995;31A Suppl 1():S1-7.
1995: B C Hüsken; J de Jong; B Beekman; R C A Onderwater; Wim J F van der Vijgh; Aalt Bast
Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids.
Cancer chemotherapy and pharmacology 1995;37(1-2):55-62.
1994: Wim J F van der Vijgh; Godefridus J Peters
Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
Seminars in oncology 1994;21(5 Suppl 11):2-7.
1994: Emile E Voest; Saskia van Acker; Wim J F van der Vijgh; B Sweder van Asbeck; Aalt Bast
Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Journal of molecular and cellular cardiology 1994;26(9):1179-85.
1994: P J Elders; Paul Lips; JAN COEN NETELENBOS; FC Van Ginkel; E Khoe; Wim J F van der Vijgh; Paul van der Stelt
Long-term effect of calcium supplementation on bone loss in perimenopausal women.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(7):963-70.
1994: A J Sips; JAN COEN NETELENBOS; Rob Barto; C A Verburgh; C Nieboer; Wim J F van der Vijgh
Topically applied low-dose calcitriol has no calciotropic effect in patients with stable plaque psoriasis.
Journal of the American Academy of Dermatology 1994;30(6):966-9.
1994: A J Sips; JAN COEN NETELENBOS; Rob Barto; Paul Lips; Wim J F van der Vijgh
One-hour test for estimating intestinal absorption of calcium by using stable strontium as a marker.
Clinical chemistry 1994;40(2):257-9.
1994: M Treskes; Epie Boven; A A van de Loosdrecht; J F Wijffels; J Cloos; Godefridus J Peters; HERBERT PINEDO; Wim J F van der Vijgh
Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
European journal of cancer (Oxford, England : 1990) 1994;30A(2):183-7.
1993: I Klein; J Welink; Wim J F van der Vijgh
Determination of Elsamitrucin (BMY-28090) in plasma and urine by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1993;622(2):249-53.
1993: H E van der Wiel; Paul Lips; J Nauta; G Kwakkel; G Hazenberg; JAN COEN NETELENBOS; Wim J F van der Vijgh
Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1993;8(12):1459-65.
1993: Klaas Kramer; Saskia van Acker; HP Voss; J A Grimbergen; Wim J F van der Vijgh; Aalt Bast
Use of telemetry to record electrocardiogram and heart rate in freely moving mice.
Journal of pharmacological and toxicological methods 1993;30(4):209-15.
1993: Saskia van Acker; Emile E Voest; D B Beems; H T Madhuizen; J de Jong; Aalt Bast; Wim J F van der Vijgh
Cardioprotective properties of O-(beta-hydroxyethyl)-rutosides in doxorubicin-pretreated BALB/c mice.
Cancer research 1993;53(19):4603-7.
1993: O R Leeuwenkamp; H E van der Wiel; Paul Lips; Wim J F van der Vijgh; Rob Barto; H Greuter; JAN COEN NETELENBOS
Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol.
European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies 1993;31(7):419-26.
1993: M Treskes; Wim J F van der Vijgh
WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Cancer chemotherapy and pharmacology 1993;33(2):93-106.
1992: J de Jong; G J Geijssen; C N Munniksma; Jan B Vermorken; Wim J F van der Vijgh
Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(12):1897-906.
1992: M Treskes; L Nijtmans; A M Fichtinger-Schepman; Wim J F van der Vijgh
Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Anticancer research 1992;12(6B):2261-5.
1992: M Treskes; Epie Boven; U Holwerda; HERBERT PINEDO; Wim J F van der Vijgh
Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Cancer research 1992;52(8):2257-60.
1992: M Treskes; L G Nijtmans; A M Fichtinger-Schepman; Wim J F van der Vijgh
Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Biochemical pharmacology 1992;43(5):1013-9.
1992: J de Jong; C N Munniksma; W S Guérand; A Bast; Wim J F van der Vijgh
Fully automated determination of a new anthracycline N-l-leucyldoxorubicin and six metabolites in plasma by high-performance liquid chromatography with on-line sample handling.
Journal of chromatography 1992;574(2):273-81.
1992: J de Jong; I Klein; A Bast; Wim J F van der Vijgh
Analysis and pharmacokinetics of N-l-leucyldoxorubucin and metabolites in tissues of tumor-bearing BALB/c mice.
Cancer chemotherapy and pharmacology 1992;31(2):156-60.
1992: J A M Van Laar; Clasina L Van der Wilt; M Treskes; Wim J F van der Vijgh; Godefridus J Peters
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
Cancer chemotherapy and pharmacology 1992;31(2):97-102.
1992: M Treskes; U Holwerda; L G Nijtmans; HERBERT PINEDO; Wim J F van der Vijgh
The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Cancer chemotherapy and pharmacology 1992;29(6):467-70.
1992: Godefridus J Peters; Clasina L Van der Wilt; F Gyergyay; J A M Van Laar; M Treskes; Wim J F van der Vijgh; HERBERT PINEDO
Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil.
International journal of radiation oncology, biology, physics 1992;22(4):785-9.
1991: M Treskes; U Holwerda; I Klein; HERBERT PINEDO; Wim J F van der Vijgh
The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Biochemical pharmacology 1991;42(11):2125-30.
1991: Wim J F van der Vijgh
Clinical pharmacokinetics of carboplatin.
Clinical pharmacokinetics 1991;21(4):242-61.
1991: J de Jong; W S Guérand; P R Schoofs; A Bast; Wim J F van der Vijgh
Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detection.
Journal of chromatography 1991;570(1):209-16.
1991: JAN COEN NETELENBOS; FC Van Ginkel; Paul Lips; O R Leeuwenkamp; Rob Barto; Wim J F van der Vijgh; H van der Wiel; W H Hackeng
Effect of a single infusion of aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored during 2 months.
The Journal of clinical endocrinology and metabolism 1991;72(1):223-8.
1991: O R Leeuwenkamp; J P Neijt; Wim J F van der Vijgh; HERBERT PINEDO
Reaction kinetics of cisplatin and its monoaquated species with the modulating agents (di)mesna and thiosulphate.
European journal of cancer (Oxford, England : 1990) 1991;27(10):1243-7.
1991: B C Tanis; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H Gall; A T van Oosterom; G Simonetti; J G McVie; Wim J F van der Vijgh; HERBERT PINEDO
Phase I study of spiroplatin.
European journal of cancer (Oxford, England : 1990) 1991;27(3):268-73.
1990: O R Leeuwenkamp; Wim J F van der Vijgh; B C Hüsken; Paul Lips; JAN COEN NETELENBOS
Human pharmacokinetics of orally administered strontium.
Calcified tissue international 1990;47(3):136-41.
1990: J de Jong; P A Maessen; A Akkerdaas; S F Cheung; HERBERT PINEDO; Wim J F van der Vijgh
Sensitive method for the determination of daunorubicin and all its known metabolites in plasma and heart by high-performance liquid chromatography with fluorescence detection.
Journal of chromatography 1990;529(2):359-68.
1990: Godefridus J Peters; Gilberto Schwartsmann; J C Nadal; E J Laurensse; Cees J van Groeningen; Wim J F van der Vijgh; HERBERT PINEDO
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Cancer research 1990;50(15):4644-9.
1990: Paul Lips; FC Van Ginkel; JAN COEN NETELENBOS; A Wiersinga; Wim J F van der Vijgh
Lower mobility and markers of bone resorption in the elderly.
Bone and mineral 1990;9(1):49-57.
1990: Wim J F van der Vijgh; P A Maessen; HERBERT PINEDO
Comparative metabolism and pharmacokinetics of doxorubicin and 4'-epidoxorubicin in plasma, heart and tumor of tumor-bearing mice.
Cancer chemotherapy and pharmacology 1990;26(1):9-12.
1990: Gilberto Schwartsmann; P Dodion; Jan B Vermorken; Wim W ten Bokkel Huinink; J Joggi; B Winograd; H Gall; G Simonetti; Wim J F van der Vijgh; M B van Hennik
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies.
Cancer chemotherapy and pharmacology 1990;25(5):345-51.
1989: Gilberto Schwartsmann; Wim J F van der Vijgh; M B van Hennik; I Klein; Jan B Vermorken; P Dodion; Wim W ten Bokkel Huinink; G Joggi; H Gall; N Crespeigne
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
European journal of cancer & clinical oncology 1989;25(12):1675-81.
1989: M Jongen; Wim J F van der Vijgh; JAN COEN NETELENBOS; G J Postma; Paul Lips
Pharmacokinetics of 24,25-dihydroxyvitamin D3 in humans.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 1989;21(10):577-80.
1989: O R Leeuwenkamp; Wim J F van der Vijgh; B C Hüsken; Paul Lips; JAN COEN NETELENBOS
Quantification of strontium in plasma and urine with flameless atomic absorption spectrometry.
Clinical chemistry 1989;35(9):1911-4.
1988: Paul Lips; A Wiersinga; FC Van Ginkel; M J Jongen; JAN COEN NETELENBOS; W H Hackeng; P D Delmas; Wim J F van der Vijgh
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects.
The Journal of clinical endocrinology and metabolism 1988;67(4):644-50.
1988: Wim J F van der Vijgh; D van Velzen; J S van der Poort; Hennie M M Schlüper; K Mross; J Feijen; HERBERT PINEDO
Morphometric study of myocardial changes during doxorubicin-induced cardiomyopathy in mice.
European journal of cancer & clinical oncology 1988;24(10):1603-8.
1988: Wim J F van der Vijgh; F Elferink; Jan B Vermorken; Wim W ten Bokkel Huinink; I Klein; H E Gall; G Simonetti; J G McVie; HERBERT PINEDO
Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.
European journal of cancer & clinical oncology 1988;24(4):621-7.
1988: K Mross; P Maessen; Wim J F van der Vijgh; H Gall; Epie Boven; HERBERT PINEDO
Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(3):517-26.
1988: P A Maessen; HERBERT PINEDO; K B Mross; Wim J F van der Vijgh
New method for the determination of doxorubicin, 4'-epidoxorubicin and all known metabolites in cardiac tissue.
Journal of chromatography 1988;424(1):103-10.
1988: M J Jongen; S Kuiper; Wim J F van der Vijgh; Paul Lips; JAN COEN NETELENBOS
Improvements in the simultaneous determination of calcidiol and calcitriol in human serum or plasma.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1988;26(1):25-8.
1988: F Elferink; Wim J F van der Vijgh; I Klein; Wim W ten Bokkel Huinink; Ria Dubbelman; J G McVie
Pharmacokinetics of carboplatin after intraperitoneal administration.
Cancer chemotherapy and pharmacology 1988;21(1):57-60.
1987: Paul Lips; FC Van Ginkel; M J Jongen; F Rubertus; Wim J F van der Vijgh; JAN COEN NETELENBOS
Determinants of vitamin D status in patients with hip fracture and in elderly control subjects.
The American journal of clinical nutrition 1987;46(6):1005-10.
1987: F Elferink; Wim J F van der Vijgh; I Klein; Jan B Vermorken; H E Gall; HERBERT PINEDO
Pharmacokinetics of carboplatin after i.v. administration.
Cancer treatment reports 1987;71(12):1231-7.
1987: M B van Hennik; Wim J F van der Vijgh; I Klein; F Elferink; Jan B Vermorken; B Winograd; HERBERT PINEDO
Comparative pharmacokinetics of cisplatin and three analogues in mice and humans.
Cancer research 1987;47(23):6297-301.
1987: Wim J F van der Vijgh; D Van Velzen; J S Van der Poort; Hennie M M Schlüper; K Mross; J Feijen; HERBERT PINEDO
Morphometric study of myocardial changes during puromycin aminonucleoside induced nephropathy in rats.
Anticancer research 1987;7(6):1111-5.
1987: F Elferink; Wim J F van der Vijgh; Wim W ten Bokkel Huinink; Jan B Vermorken; I Klein; B Winograd; M Tish Knobf; G Simonetti; H E Gall; J G McVie
Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.
British journal of cancer 1987;56(4):479-83.
1987: P A Maessen; K B Mross; HERBERT PINEDO; Wim J F van der Vijgh
Improved method for the determination of 4'-epidoxorubicin and seven metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography 1987;417(2):339-46.
1987: K Mross; P Maessen; Wim J F van der Vijgh; J F Bogdanowicz; K H Kurth; HERBERT PINEDO
Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder.
European journal of cancer & clinical oncology 1987;23(5):505-8.
1987: P A Maessen; K B Mross; HERBERT PINEDO; Wim J F van der Vijgh
Metabolism of epidoxorubicin in animals: absence of glucuronidation.
Cancer chemotherapy and pharmacology 1987;20(1):85-7.
1986: JAN COEN NETELENBOS; Henk Asscheman; Paul Lips; Wim J F van der Vijgh; M J Jongen; FC Van Ginkel; W H Hackeng
Absence of effect of 24,25-dihydroxyvitamin D3 in primary hyperparathyroidism.
The Journal of clinical endocrinology and metabolism 1986;63(1):246-8.
1986: B Winograd; Jan B Vermorken; Wim W ten Bokkel Huinink; G Simonetti; H E Gall; M Tish Knobf; Wim J F van der Vijgh; J G McVie; HERBERT PINEDO
Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.
Cancer research 1986;46(4 Pt 2):2148-51.
1985: Epie Boven; M M Nauta; H M Schluper; F Elferink; Wim J F van der Vijgh; HERBERT PINEDO
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
European journal of cancer & clinical oncology 1985;21(10):1253-60.
1985: JAN COEN NETELENBOS; M J Jongen; Wim J F van der Vijgh; Paul Lips; FC Van Ginkel
Vitamin D status in urinary calcium stone formation.
Archives of internal medicine 1985;145(4):681-4.
1985: Epie Boven; Wim J F van der Vijgh; M M Nauta; Hennie M M Schlüper; HERBERT PINEDO
Comparative activity and distribution studies of five platinum analogues in nude mice bearing human ovarian carcinoma xenografts.
Cancer research 1985;45(1):86-90.
1985: Paul Lips; R Bouillon; M J Jongen; FC Van Ginkel; Wim J F van der Vijgh; JAN COEN NETELENBOS
The effect of trauma on serum concentrations of vitamin D metabolites in patients with hip fracture.
Bone 1985;6(2):63-7.
1984: M J Jongen; FC Van Ginkel; Wim J F van der Vijgh; S Kuiper; JAN COEN NETELENBOS; Paul Lips
An international comparison of vitamin D metabolite measurements.
Clinical chemistry 1984;30(3):399-403.
1984: M J Jongen; Wim J F van der Vijgh; Paul Lips; JAN COEN NETELENBOS
Measurement of vitamin D metabolites in anephric subjects.
Nephron 1984;36(4):230-4.
1982: M J Jongen; Wim J F van der Vijgh; E C van Beresteyn; H van den Berg; R Bosch; T Hoogenboezem; T J Visser; JAN COEN NETELENBOS
Interlaboratory variation of vitamin D1) metabolite measurements.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1982;20(10):753-6.
1982: Paul Lips; JAN COEN NETELENBOS; M J Jongen; FC Van Ginkel; A L Althuis; C L van Schaik; Wim J F van der Vijgh; J P Vermeiden; C van der Meer
Histomorphometric profile and vitamin D status in patients with femoral neck fracture.
Metabolic bone disease & related research 1982;4(2):85-93.
1981: M J Jongen; Wim J F van der Vijgh; H J Willems; JAN COEN NETELENBOS; Paul Lips
Simultaneous determination of 25-hydroxyvitamin D, 24,25-dihydroxyvitamin D, and 1,25-dihydroxyvitamin D in plasma or serum.
Clinical chemistry 1981;27(10):1757-60.
1981: M J Jongen; Wim J F van der Vijgh; H J Willems; JAN COEN NETELENBOS
Analysis for 1,25-dihydroxyvitamin D in human plasma, after a liquid-chromatographic purification procedure, with a modified competitive protein-binding assay.
Clinical chemistry 1981;27(3):444-50.